Skip to content

Study · Non-randomized trial · n = 11 · 1986

4 results

[Clinical use of Gonadorelin as a diagnostic agent in one- and two-step tests].

Vesper B, Rohde W, Groot-Wassink T

Zentralblatt fur Gynakologie1 Jan 1986

PMID3103350 (opens in a new tab)PepBankPUB-03103350
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In 11 women with a normal menstrual cycle in mid follicular phase, gonadorelin provoked a typical gonadotropin release.

    In plain wordsIn 11 women with a normal cycle, gonadorelin caused a typical release of gonadotropins.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseGonadotropin release in women with a normal cycle
    Study

    n = 11

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was proved as a very effective drug, which provoked a typical gonadotropin release.
    1 context sentence
    Summary · context
    Synthetic LH/RH Gonadorelin, produced by VEB Berlin-Chemie, was given to 11 women with a normal menstrual cycle during the middle of the follicle phase.
  2. 02HumanNon-randomized trialActivity measurement

    In 10 patients with secondary amenorrhea, a first intravenous injection of 80 micrograms gonadorelin produced a gonadotropin peak, in particular for LH, after 30 to 60 minutes.

    In plain wordsIn 10 women with secondary amenorrhea, an intravenous dose of gonadorelin produced a peak in gonadotropins, mainly LH, after 30 to 60 minutes.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    IncreaseGonadotropin peak after first gonadorelin injection in secondary amenorrhea
    Study

    n = 10

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    80 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    Also 10 patients with a secondary amenorrhea responded already to the first intravenous injection of 80 micrograms Gonadorelin with a peak level of gonadotropins, in particular with LH levels, after 30 to 60 minutes (delta 1 = 1 st peak level--0' level).
  3. 03HumanNon-randomized trialActivity measurement

    The relative gonadotropin rise after a second intravenous 80 microgram gonadorelin dose, given 120 minutes after the first, was not significantly higher than after the first dose.

    In plain wordsA second gonadorelin dose 120 minutes after the first did not raise gonadotropins significantly more than the first dose.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    No significant changeSecond-step versus first-step gonadotropin rise
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    80 micrograms · intravenousAs given in this study (human).

    Source sentences

    Summary
    The relative ascent of gonadotropins (delta 2 = 2nd peak level--120' level) after the second step i.v. administration of 80 micrograms Gonadorelin at a 120 minutes interval was not significantly higher than delta 1.
  4. 04HumanNon-randomized trialOther

    The pituitary reaction to LH/RH did not immediately depend on the basal gonadotropin level.

    In plain wordsHow strongly the pituitary reacted to LH/RH did not immediately depend on the starting gonadotropin level.

    Peptide
    Gonadorelin (GnRH, LHRH)
    Outcome
    No significant changeDependence of pituitary reaction on basal gonadotropin level
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The reaction of pituitary on LH/RH does not immediately depend on the basal level of gonadotropin values.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.